Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis

Sik-Kwan Chan,Horace Cheuk-Wai Choi,Victor Ho-Fun Lee

JTO Clinical and Research Reports（2022）

引用 5|浏览3

暂无评分

摘要

In Asian patients harboring L858R mutation, TKIs and combination treatments had no OS benefit when compared with conventional chemotherapies. Further studies are warranted to investigate the resistance mechanism with TKIs and potential combination strategies in patients with this common but less favorable mutation.

查看译文

关键词

Non–small-cell lung cancer,Epidermal growth factor receptor,L858R mutation,Tyrosine kinase inhibitors,Asian

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要